, Tracking Stock Market Picks
Enter Symbol:
Insys Therapeutics Inc. (INSY) [hlAlert]

up 496.66 %

Insys Therapeutics Inc. (INSY) rated Outperform by Wells Fargo

Posted on: Wednesday,  Jul 31, 2013  9:25 AM ET by Wells Fargo

Wells Fargo rated Outperform Insys Therapeutics Inc. (NASDAQ: INSY) on 07/31/2013, when the stock price was $5.57. Since
then, Insys Therapeutics Inc. has gained 496.67% as of 01/26/2016's recent price of $33.25.
If you would have followed this Wells Fargo's recommendation on INSY, you would have gained 496.66% of your investment in 909 days.

Neopharm Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of drugs for the treatment of cancer and other diseases. The Company built its drug development program around two technology platforms: a tumor-targeting toxin platform and NeoLipid liposomal drug delivery system. Neopharm has five drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis (IPF) and asthma.

The investment research content is provided by Wells Capital Management, a registered investment adviser and wholly owned subsidiary of Wells Fargo Bank, N.A. Our economists’ expertise on domestic markets, and national and global trends, is an important resource to the firm. Wells Capital Management economists are known for their thoughts on investment strategy, macro-economic forecasts and other top-down analysis, and share their views on bonds, midcaps and liquidity management in their publications.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/31/2013 9:25 AM Buy
as of 12/13/2013
1 Week down  -19.43 %
1 Month down  -14.10 %
3 Months up  9.52 %
1 YTD up  132.21 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy